KEGG   DRUG: Bavunalimab
Entry
D12317                      Drug                                   
Name
Bavunalimab (USAN/INN);
Pavunalimab
Formula
C5576H8597N1481O1737S36
Exact mass
125248.9856
Mol weight
125326.1439
Sequence
(Chain A)
EVQLVESGGG LVKPGGSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVSF ISYDGNYKYY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARGG HLGPFDLWGQ GTMVTVSSGK
PGSGKPGSGK PGSGKPGSEI VLTQSPATLS LSPGERATLS CRASQSVGSS YLAWYQQKPG
QAPRLLIYGA SSRATGIPDR FSGSGSGTDF TLTISRLEPE DFAVYYCQQY GSSPWTFGQG
TKVEIKEPKS SDKTHTCPPC PAPPVAGPSV FLFPPKPKDT LMISRTPEVT CVVVDVKHED
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA
PIEKTISKAK GQPREPQVYT LPPSREQMTK NQVKLTCLVK GFYPSDIAVE WESNGQPENN
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVLHE ALHSHYTQKS LSLSPGK
(Chain B)
EVQLVESGGG LVQPGGSLRL SCAASGFTFD DAWMSWVRQA PGKGLEWVAE ISTKANNHAT
YYAESVKGRF TISRDDSKSS VYLQMNSLRA EDTAVYYCTR LATWDWYFDV
WGQGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG
VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SDTKVDKKVE PKSCDKTHTC
PPCPAPPVAG PSVFLFPPKP KDTLMISRTP EVTCVVVDVK HEDPEVKFNW YVDGVEVHNA
KTKPREEEYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ
VYTLPPSREE MTKNQVSLTC DVSGFYPSDI AVEWESDGQP ENNYKTTPPV LDSDGSFFLY
SKLTVDKSRW EQGDVFSCSV LHEALHSHYT QKSLSLSPGK
(Chain C)
DIVLTQSPSS LSASVGDRVT ITCRASQSVD YDGDSYMNWY QQKPGKPPKL LIYAASELES
GIPARFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPF TFGSGTKLEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: A22-A96, A161-A227, A257-B230, A260-B233, A291-A351, A397-A455, B22-B98, B148-B204, B224-C218, B264-B324, B370-B428, C23-C92, C138-C198)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor
  Type
Monoclonal antibody, bispecific antibody
Target
CTLA4 (CD152) [HSA:1493] [KO:K06538]
LAG3 (CD223) [HSA:3902] [KO:K06565]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12317  Bavunalimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D12317  Bavunalimab (USAN/INN)
   CD molecules
    LAG3 (CD223)
     D12317  Bavunalimab (USAN/INN)
Other DBs
CAS: 2329669-78-3
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system